Evidence map›Paper›PMID 40073718›Full record

ArticleThe International journal on drug policy2025

Attitudes toward and experience with naloxone among people who use drugs in the Southeastern United States.

Mylinh H Le, Tanja C Laschober, Susan Tross, Margaret Paschen-Wolff, Melissa M Ertl, Lynette Wright, Mary A Hatch

Abstract read
In one paragraph

Article in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mylinh H LeUniversity of Washington School of Medicine, Seattle, WA, USA. Electronic address: mylinhle@uw.edu.
Tanja C LaschoberUniversity of Washington Medicine, Department of Psychiatry & Behavioral Sciences, Addictions, Drug & Alcohol Institute, Seattle, WA, USA.
Susan TrossColumbia University, Department of Psychiatry, New York, NY, USA.
Margaret Paschen-WolffColumbia University, Department of Psychiatry, New York, NY, USA.
Melissa M ErtlUniversity of Minnesota, Department of Psychology, Minneapolis, MN, USA.
Lynette WrightUniversity of Washington Medicine, Department of Psychiatry & Behavioral Sciences, Addictions, Drug & Alcohol Institute, Seattle, WA, USA.
Mary A HatchUniversity of Washington Medicine, Department of Psychiatry & Behavioral Sciences, Addictions, Drug & Alcohol Institute, Seattle, WA, USA. Electronic address: hatchm@uw.edu.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
INSPIRE : Interdisciplinary Social and Behavioral Science Prevention and Intervention REsearch in HIVT32MH019139 · NIMH · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Claude Ann Mellins, Jae M. Sevelius · 1989 to 2026
$10.8M
The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western StatesR25DA050985 · NIDA · UNIVERSITY OF WASHINGTON · PI Judith Tsui · 2020 to 2026
$2.6M
Enhanced Interdisciplinary Research Training InstituteR25DA050687 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VALDEZ, AVELARDO · 2020 to 2024
$1.3M
NIDA NIH HHS R25 DA050687NIDA NIH HHS R25DA050687-01A1NIDA NIH HHS R25 DA050985NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714NIMH NIH HHS T32 MH019139
6 · The paper itself

Abstract

backgroundThe opioid epidemic presses on as a significant public health issue in the U.S., with particularly high overdose death rates in the Southeast. Naloxone is the standard of care for reversing opioid overdose; however, many people who use drugs (PWUD) experience barriers to naloxone use. This cross-sectional survey study aims to describe awareness of, experience with, willingness, barriers, and distribution strategies for naloxone among PWUD in the Southeast.

methodsData were obtained from a larger implementation survey study. Descriptive analyses focused on N = 381 people in substance use treatment programs, syringe services programs, and sexually transmitted infection clinics who reported non-prescription opioid use in the past 12 months and completed a naloxone-related questionnaire.

resultsMost PWUD reported using opioids daily (60-62 %). 82 % had previously heard of naloxone, but only 43 % reported having received any type of training to use it. On a 5-point scale, PWUD without prior training (n = 219) reported being very willing to be trained to use naloxone on someone who overdoses (Mdn=5.00, IQR=2.00). Among all PWUD, not knowing where to go for naloxone training was the only barrier to using naloxone that was endorsed with certainty (Mdn=4.00, IQR=2.00). PWUD endorsed three strategies to improve naloxone distribution, including wanting their site to offer naloxone training (Mdn=4.00, IQR=1.00), increased access to naloxone education (Mdn=4.00, IQR=1.00), and connecting people to training programs (Mdn=4.00, IQR=1.00).

conclusionThis study suggests that improvements are still needed in the saturation of naloxone training and distribution among PWUD, including in settings that provide non-opioid related services.

Indexed as

Drug UsersHealth Knowledge, Attitudes, PracticeNaloxoneNarcotic AntagonistsOpiate OverdoseOpioid-Related DisordersAdultCross-Sectional StudiesDrug OverdoseFemaleHumansMaleMiddle AgedSoutheastern United StatesSurveys and QuestionnairesYoung AdultNaloxoneNarcotic AntagonistsFentanylNaloxoneOpioid overdosePeople who use drugsSubstance use

Identifiers

PMID40073718
PMCPMC12034464

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.